StockData
LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Lifevantage Corp

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026
$5.98−0.02 (-0.33%)

Close on Oct 19, 2026

Market cap
$74.97M
P/E (TTM)
15.0
Dividend yield
3.09%

Earnings

Next report expected Nov 3, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q4 FY2026
Ended Jun 30, 2026
Aug 27, 2026After market close$42.40M$0.10$0.11
Q3 FY2026
Ended Mar 31, 2026
May 6, 2026After market close$43.70M$0.11$0.12
Q2 FY2026
Ended Dec 31, 2025
Feb 4, 2026After market close$48.90M$0.02$0.15
Q1 FY2026
Ended Sep 30, 2025
Nov 4, 2025After market close$47.60M$0.17$0.18
Q4 FY2025
Ended Jun 30, 2025
Sep 4, 2025After market close$55.10M$0.15$0.17
Q3 FY2025
Ended Mar 31, 2025
May 6, 2025After market close$58.40M$0.26$0.26
Q2 FY2025
Ended Dec 31, 2024
Feb 5, 2025After market close$67.80M$0.19$0.22
Q1 FY2025
Ended Sep 30, 2024
Oct 29, 2024After market close$47.20M$0.14$0.15
Q4 FY2024
Ended Jun 30, 2024
Aug 28, 2024After market close$48.90M$0.10$0.14
Q3 FY2024
Ended Mar 31, 2024
May 2, 2024After market close$48.20M$0.13$0.21
Q2 FY2024
Ended Dec 31, 2023
Jan 30, 2024After market close–––

Company guidance

Outlook given with results on May 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
full year tax ratefull year18% to 20%Lowered

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Lifevantage filed with the SEC